Related Experiment Video
Updated: Feb 19, 2026
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Selective Estrogen Receptor Modulators (SERMs): Advances, Challenges, and Future Prospects in ER+ Breast Cancer
Anurag Saini1, Ripunjay Kalita1, Tirtha Nath1
1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Guwahati, Assam, India.
Abstract:
Selective estrogen receptor modulators (SERMs) are an important class of drugs mainly useful in the treatment of breast cancer as they act as estrogen antagonists in the breast tissue but have an agonistic activity in bone and the cardiovascular system (CVS). ER-positive breast cancer, driven by estrogen signaling, is the most prevalent subtype worldwide. SERMs remain essential therapeutics, antagonizing estrogen activity in breast tissue while retaining agonist effects in bone and CVS. While traditional reviews have focused on triphenylethylene and benzothiophene scaffolds, this review provides a novel, insightful comprehensive analysis of emerging heterocyclic SERMS-including indole, benzimidazole, coumarin, benzopyran, organometallic, and phytoestrogen derivatives-linking chemical diversity with tissue-selective mechanisms and structure-activity relationships. Major limitations include incomplete receptor subtype selectivity, metabolic instability, partial agonism in nontarget tissues, and acquired endocrine resistance driven by ER mutations and growth factor signaling. This work uniquely integrates structural, mechanistic, and therapeutic insights and highlights innovative strategies, including dual SERM-SERD scaffolds, combination with aromatase inhibitors, and computationally guided subtype-selective design to overcome resistance, improve potency, and optimize clinical outcomes in ER-positive breast cancer therapy.
Insights
Emerging heterocyclic drugs offer new hope for treating estrogen-receptor-positive breast cancer by selectively targeting cancer cells while preserving beneficial effects in bone and the cardiovascular system.
Area of Science:
- Pharmacology
- Oncology
- Medicinal Chemistry
Background:
- Selective estrogen receptor modulators (SERMs) are crucial for treating estrogen-driven breast cancer.
- SERMs act as estrogen antagonists in breast tissue but agonists in bone and cardiovascular system (CVS).
- Estrogen-receptor-positive breast cancer is the most common subtype globally.
Purpose of the Study:
- To provide a comprehensive analysis of emerging heterocyclic SERMs beyond traditional scaffolds.
- To link chemical diversity with tissue-selective mechanisms and structure-activity relationships.
- To highlight innovative strategies for overcoming limitations and improving therapeutic outcomes.
Main Methods:
- Review of emerging heterocyclic SERM scaffolds (indole, benzimidazole, coumarin, benzopyran, organometallic, phytoestrogen derivatives).
- Analysis of tissue-selective mechanisms and structure-activity relationships.
- Integration of structural, mechanistic, and therapeutic insights.
Main Results:
- Identified limitations of current SERMs: incomplete selectivity, metabolic instability, partial agonism, and endocrine resistance.
- Highlighted novel heterocyclic SERMs with potential for improved efficacy.
- Discussed innovative strategies to overcome resistance and enhance potency.
Conclusions:
- Emerging heterocyclic SERMs represent a promising avenue for ER-positive breast cancer therapy.
- Addressing limitations like resistance and selectivity is key to optimizing clinical outcomes.
- Combination therapies and computational design offer pathways to improved treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...